In the SURMOUNT-4 trial, 100 patients with obesity were on tirezpatide for 9 months, and the average weight loss was 20.9 percent. The patients were then randomized to receive either placebo with behavioral intervention or tirzepatide for another year, and the patients in the former group regained a significant amount of weight. Dive further into the study’s findings and implications with Dr. John Buse and Dr. Louis Aronne, the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medical College in New York.